Adicet Bio (ACET) “announced the pricing of an underwritten registered direct offering of 70,001,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 10,000,000 shares of common stock. Jefferies and Guggenheim Securities are acting as joint book-running managers for the offering. Truist Securities is also acting as a joint bookrunner. Wedbush PacGrow and H.C. Wainwright & Co. are acting as lead managers for the offering.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACET:
- Adicet Bio Announces Major Stock Offering Agreement
- Adicet Bio Reports Promising Phase 1 Study Results
- Adicet Bio’s ADI-001 shows positive preliminary Phase 1 results in LN and SLE
- Adicet Bio’s Promising CAR γδ T Cell Therapy: A Buy Rating Amidst Anticipated Breakthroughs in Lupus Treatment
- Adicet Bio’s Promising Developments and Strategic Advancements Justify Buy Rating